ChromaDex FY2024 EPS Forecast Boosted by HC Wainwright

ChromaDex Co. (NASDAQ:CDXC) – Equities research analysts at HC Wainwright boosted their FY2024 earnings per share (EPS) estimates for ChromaDex in a report released on Monday, November 4th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of $0.06 for the year, up from their previous forecast of $0.03. HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for ChromaDex’s current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for ChromaDex’s Q4 2024 earnings at $0.04 EPS, Q1 2025 earnings at $0.04 EPS, Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at $0.05 EPS and Q4 2025 earnings at $0.06 EPS.

ChromaDex (NASDAQ:CDXC) last issued its quarterly earnings results on Thursday, October 31st. The company reported $0.02 EPS for the quarter. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. The company had revenue of $25.58 million during the quarter, compared to analysts’ expectations of $23.70 million. During the same quarter in the previous year, the company earned ($0.01) EPS.

Separately, Roth Mkm upped their price target on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday.

ChromaDex Trading Up 14.4 %

NASDAQ CDXC opened at $6.99 on Tuesday. ChromaDex has a 12 month low of $1.32 and a 12 month high of $7.08. The stock has a 50-day simple moving average of $3.70 and a 200 day simple moving average of $3.28. The company has a market capitalization of $530.77 million, a PE ratio of 699.00 and a beta of 1.88.

Insider Buying and Selling

In other ChromaDex news, Director Kristin Patrick sold 23,000 shares of ChromaDex stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $3.57, for a total value of $82,110.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 9.64% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. OneDigital Investment Advisors LLC raised its holdings in ChromaDex by 5.5% during the third quarter. OneDigital Investment Advisors LLC now owns 59,414 shares of the company’s stock worth $217,000 after acquiring an additional 3,097 shares in the last quarter. BSW Wealth Partners acquired a new position in shares of ChromaDex during the 3rd quarter worth approximately $324,000. SG Americas Securities LLC bought a new stake in shares of ChromaDex during the 3rd quarter worth approximately $61,000. The Manufacturers Life Insurance Company acquired a new stake in shares of ChromaDex in the 2nd quarter valued at approximately $31,000. Finally, Marshall Wace LLP acquired a new stake in shares of ChromaDex in the 2nd quarter valued at approximately $56,000. Institutional investors and hedge funds own 15.41% of the company’s stock.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.